May 15th 2024
Phase 1 of the Acclaim-3 study evaluating quaratusugene ozeplasmid plus atezolizumab in patients with extensive-stage small cell lung cancer has enrolled and dosed its first patient.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Immunotherapy Generates Hope for the Treatment of Small Cell Lung Cancer
October 20th 2022In an interview with Targeted Oncology, Gene G. Finley discussed the many wins and losses experts have seen in the small cell lung cancer space. He also explained his hopes for the future of this space.
Read More
Dowlati Compares the Advantages and Disadvantages of Atezolizumab and Durvalumab in ES-SCLC
October 17th 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.
Read More
Roundtable Discussion: Iams Considers Platinum Rechallenge or Other Therapy for Relapsed ES-SCLC
September 22nd 2022During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.
Read More
Roundtable Discussion: Kandra Explores Benefit of Chemoimmunotherapy for Small Cell Lung Cancer
August 28th 2022During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.
Read More
PARP Inhibitor Regimen Leads to Promising ORR in ES-SCLC
August 8th 2022The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.
Read More
Clinical Commentary: How Immunotherapy Is Used for Treatment of Patients with ES-SCLC and NSCLC
July 27th 2022At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.
Read More
Roundtable Discussion: Mohamed Analyzes Data for Understanding ES-SCLC Treatment
July 18th 2022During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.
Read More
Real-World Implications of the IMpower133 Trial in ES-SCLC
June 28th 2022Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.
Watch
Roundtable Discussion: Dowlati Breaks Down Updated Treatment Data in SCLC
June 20th 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed with participants the results of the CASPIAN and IMpower 133 trials of new regimens for extensive-stage small cell lung cancer.
Read More
PP2A Inhibitions May Address Transformation of NSCLC to SCLC in Patients With EGFR+ Disease
March 29th 2022In an interview with Targeted Oncology, Ravi Salgia, MD, PhD, discussed the research leading to the first-in-human study of LB-100 combined with chemotherapy or immunotherapy to address transformation to small cell lung cancer.
Read More